Table 3.
p16INK4a and NF-κB immunoreactivity in different anatomical sites of B19V-positive and -negative HNSCCs
| HNSCC anatomic site N (%) |
|||||||
|---|---|---|---|---|---|---|---|
| Tongue N = 38 |
Oral cavity N = 34 |
Larynx N = 13 |
Hypopharynx N = 9 |
Nasopharynx N = 8 |
Tonsil N = 6 |
||
| B19V DNA (+) | p16INK4a (+) | 3 (7.9) | 4 (14.8) | 2 (18.2) | 0 | 2 (28.6) | 2 (40) |
| p16INK4a (-) | 9 (23.7) | 5 (18.5) | 3 (27.3) | 3 (33.3) | 1 (14.3) | 0 | |
| B19V DNA (−) | p16INK4a (+) | 6 (15.8) | 9 (33.3) | 2 (18.2) | 1 (11.1) | 0 | 1 (20) |
| p16INK4a (-) | 20 (52.6) | 9 (33.3) | 4 (36.4) | 5 (55.6) | 4 (57.1) | 2 (40) | |
| B19V DNA (+) | High cytoplasmic NF-κB expression | 8 (21.6) | 10 (31.3) | 4 (33.3) | 2 (25) | 2 (28.6) | 1 (20) |
| Low cytoplasmic NF-κB expression | 4 (10.8) | 1 (3.1) | 1 (8.3) | 1 (12.5) | 1 (14.3) | 1 (20) | |
| B19V DNA (−) | High cytoplasmic NF-κB expression | 18 (48.6) | 15 (46.9) | 5 (41.7) | 4 (50) | 2 (28.6) | 2 (40) |
| Low cytoplasmic NF-κB expression | 7 (18.9) | 6 (18.8) | 2 (16.7) | 1 (12.5) | 2 (28.6) | 1 (20) | |
| B19V DNA (+) | High nuclear NF-κB expression | 0 | 4 (12.5) | 3 (25) | 2 (25) | 0 | 0 |
| Low nuclear NF-κB expression | 12 (32.4) | 7 (21.9) | 2 (16.7) | 1 (12.5) | 3 (42.9) | 2 (40) | |
| B19V DNA (−) | High nuclear NF-κB expression | 5 (13.5) | 4 (12.5) | 1 (8.3) | 3 (37.5) | 1 (14.3) | 1 (20) |
| Low nuclear NF-κB expression | 20 (54.1) | 17 (53.1) | 6 (50) | 2 (25) | 3 (42.9) | 2 (40) | |
p16INK4a, cytoplasmic NF-κB, and nuclear NF-κB immunohistochemistry were successfully performed on 97, 101, and 101 of the total 108 HNSCC specimens, respectively